Dinardo, C., Montesinos, P., Schuh, A., Papayannidis, C., Vyas, P., Wei, A., . . . De Botton, S. (2022). Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML). American Society of Clinical Oncology.
Citace podle Chicago (17th ed.)Dinardo, CD, et al. Health-related Quality of Life (HRQoL) with Enasidenib Versus Conventional Care Regimens in Older Patients with Late-stage Mutant- IDH2 Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). American Society of Clinical Oncology, 2022.
Citace podle MLA (9th ed.)Dinardo, CD, et al. Health-related Quality of Life (HRQoL) with Enasidenib Versus Conventional Care Regimens in Older Patients with Late-stage Mutant- IDH2 Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). American Society of Clinical Oncology, 2022.